关键数据
2.445今开
2.445最高
225.00成交量
0.61市盈率 TTM
亏损市盈率动
--股息TTM
0.00%换手率
2.340昨收
2.330最低
527.00成交额
亏损市盈率静
0.47市净率
0.00%股息率 TTM
48.21%ROA
4.53052周最高
0.08量比
-55.89M净利润
33.22M总股本
3.8490每股收益TTM
1.22Beta
129.25%ROE
2.18052周最低
4.92%振幅
62.00%毛利率
77.90M总市值
-2.80回报/风险
4.56%风险率

即将为您带来更多新闻,敬请期待。。。
Fortress Biotech Inc评分
-0.10与上次评分对比预测8.00
财务诊断6.76
技术分析3.84
公司估值9.70
机构认同度3.00
风险评估3.97
分析师评级
买入评级
5.000目标均价
+104.08%涨幅空间
Fortress Biotech Inc 最新财报电话会记录
Journey Medical (FBIO) 2026年第二季度业绩电话会议:Emrosi加速放量推动营收增长23%
Journey Medical 2026年第二季度业绩电话会议亮点包括:营收增长23%至1850万美元,调整后EBITDA录得正值,且 Emrosi 处方量加速增长。
财务指标
货币: USD

由于公司未披露,未能获取相关数据
货币: USD

由于公司未披露,未能获取相关数据
Fortress Biotech Inc 简介
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
行业药品
公司代码FBIO
员工数量101
国家United States of America
持股情况
| 持股股东 | 占比 |
|---|
| Rosenwald (Lindsay A) | 13.81% |
|---|
| Weiss (Michael S) | 6.85% |
|---|
| Opaleye Management Inc. | 3.28% |
|---|
| Vanguard Capital Management, LLC | 2.91% |
|---|
| 股东类型 | 占比 |
|---|
| Individual Investor | 22.79% |
|---|
| Investment Advisor | 9.55% |
|---|
| Hedge Fund | 5.62% |
|---|
| Investment Advisor/Hedge Fund | 2.48% |
|---|
常见问题
Fortress Biotech Inc(FBIO)的当前股价是多少?
Fortress Biotech Inc(FBIO)的当前股价是 2.34。
Fortress Biotech Inc的股票代码是什么?
Fortress Biotech Inc的股票代码是FBIO。
Fortress Biotech Inc股票的52周最高点是多少?
Fortress Biotech Inc股票的52周最高点是4.53。
Fortress Biotech Inc股票的52周最低点是多少?
Fortress Biotech Inc股票的52周最低点是2.18。
Fortress Biotech Inc的市值是多少?
Fortress Biotech Inc的市值是77.73M。
现在Fortress Biotech Inc(FBIO)的股票是买入、持有还是卖出?
根据分析师评级,Fortress Biotech Inc(FBIO)的总体评级为买入,目标价格为5.00。
Fortress Biotech Inc(FBIO)股票的每股收益(EPS TTM)是多少
Fortress Biotech Inc(FBIO)股票的每股收益(EPS TTM)是3.85。